{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:25:24Z","timestamp":1787034324824,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) carries a poor prognosis. Although SBRT combined with cadonilimab and lenvatinib has shown encouraging antitumor activity in a prior prospective phase II trial, marked interpatient heterogeneity remains. Gut microbiota may influence antitumor immunity and could help identify patients more or less likely to benefit from this regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterize baseline and longitudinal gut microbiota features in treatment-na\u00efve HCC patients with PVTT receiving SBRT plus cadonilimab and lenvatinib, and to explore microbial signatures associated with therapeutic response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a complementary exploratory study nested within the aforementioned phase II trial. In this prospective multicenter exploratory cohort, 23 patients from the parent trial provided 46 paired fecal samples collected before treatment (Phase A) and after 3 cycles of cadonilimab (Phase B). Patients were categorized by best mRECIST response as responders (group C, CR\/PR; n = 10) or non-responders (group D, SD\/PD; n = 13), consistent with the parent trial\u2019s grouping strategy. 16S rRNA amplicon sequencing and downstream bioinformatic analyses were performed to assess microbial diversity, differential taxa, predicted KEGG functional profiles, and exploratory discriminatory performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1,410,203 high-quality non-chimeric reads were retained and rarefied to 5,459 reads per sample. Baseline \u03b1-diversity indices were largely comparable between groups, although Faith\u2019s phylogenetic diversity was higher in responders (P\u00a0=\u00a00.0178). \u03b2-diversity did not show clear between-group separation at baseline or marked restructuring after treatment. Genus-level DESeq2 analysis identified 7 baseline differential genera.\n                      <jats:italic>Extibacter<\/jats:italic>\n                      was absent in responders but detectable in 6\/13 non-responders and showed the strongest discriminatory signal (P\u00a0=\u00a00.0179). Predicted functional analysis suggested differences in KEGG level 2 modules, and\n                      <jats:italic>[Ruminococcus]_gnavus_<\/jats:italic>\n                      group was positively correlated with \u201cimmune diseases\u201d and \u201ccarbohydrate metabolism\u201d after BH correction (q = 0.042). In exploratory ROC analysis, baseline\n                      <jats:italic>Extibacter<\/jats:italic>\n                      yielded an AUC of 0.731, increasing to 0.777 when combined with AFP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In HCC patients with PVTT treated with SBRT plus cadonilimab and lenvatinib, the overall gut microbiota architecture remained relatively stable, whereas selected baseline genus-level features were associated with therapeutic response.\n                      <jats:italic>Extibacter<\/jats:italic>\n                      showed an exploratory non-response-associated signal that requires validation in larger independent studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      , identifier NCT06040177.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1864941","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:37:26Z","timestamp":1787031446000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between gut microbiota characteristics and therapeutic efficacy of multimodal combination therapy in hepatocellular carcinoma with portal vein tumor thrombus: a secondary analysis of a prospective phase II trial"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinwen","family":"Liang","sequence":"first","affiliation":[{"name":"First Clinical Medical College, Guangxi Medical University","place":["Nanning, Guangxi, China"]},{"name":"Department of Urology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhui","family":"Liang","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Guangxi Medical University","place":["Nanning, Guangxi, China"]},{"name":"Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yan","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muyun","family":"Li","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Oncology, Foresea Life Insurance Guangxi Hospital","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]},{"name":"Guangxi Key Laboratory of Immunology and Metabolism for Liver Diseases","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabin","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Science and Education, Jiangbin Hospital of Guangxi Zhuang Autonomous Region","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1159\/000546574","article-title":"China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition)","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3760\/cma.j.cn112137-20251211-03271","article-title":"Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China(2026 edition)","volume":"106","year":"2026","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.livres.2024.09.002","article-title":"Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end","volume":"8","author":"Abdelhamed","year":"2024","journal-title":"Liver Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evidence"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(24)00247-4","article-title":"Combination locoregional and systemic therapies in hepatocellular carcinoma","volume":"10","author":"Zhong","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/cancers16051058","article-title":"Immunotherapy and radiation therapy combinatorial approaches in hepatocellular carcinoma","volume":"16","author":"Tojjari","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1687344","article-title":"Stereotactic body radiation therapy combined with cadonilimab and lenvatinib in the treatment of hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombus: a prospective, multicenter, single-arm, phase II clinical trial","volume":"16","author":"Mo","year":"2025","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s40425-019-0650-9","article-title":"Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma","volume":"7","author":"Zheng","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-19-1014","article-title":"The gut microbiome is associated with clinical response to anti-PD-1\/PD-L1 immunotherapy in gastrointestinal cancer","volume":"8","author":"Peng","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e003334","DOI":"10.1136\/jitc-2021-003334","article-title":"Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers","volume":"9","author":"Mao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e004779","DOI":"10.1136\/jitc-2022-004779","article-title":"Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"10","author":"Lee","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34118","article-title":"Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma","volume":"151","author":"Wu","year":"2022","journal-title":"Int J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1366131","article-title":"Gut microbiota as a prognostic biomarker for unresectable hepatocellular carcinoma treated with anti-PD-1 therapy","volume":"15","author":"Xin","year":"2024","journal-title":"Front Genet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e008686","DOI":"10.1136\/jitc-2023-008686","article-title":"Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma","volume":"12","author":"Zhu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2486519","article-title":"Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification","volume":"17","author":"Huang","year":"2025","journal-title":"Gut Microbes"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1568962","article-title":"Gut microbiome, a novel precision medicine biomarker for hepatocellular carcinoma","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41522-025-00786-8","article-title":"Gut microbiota shapes cancer immunotherapy responses","volume":"11","author":"Lei","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0209-9","article-title":"Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2","volume":"37","author":"Bolyen","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3869","article-title":"DADA2: High-resolution sample inference from Illumina amplicon data","volume":"13","author":"Callahan","year":"2016","journal-title":"Nat Methods"},{"key":"B27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40168-018-0470-z","article-title":"Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-feature-classifier plugin","volume":"6","author":"Bokulich","year":"2018","journal-title":"Microbiome"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-6-r60","article-title":"Metagenomic biomarker discovery and explanation","volume":"12","author":"Segata","year":"2011","journal-title":"Genome Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2676","article-title":"Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences","volume":"31","author":"Langille","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"eaan5931","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"360","author":"Ma","year":"2018","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2020.1854008","article-title":"The gut bacterium Extibacter muris produces secondary bile acids and influences liver physiology in gnotobiotic mice","volume":"13","author":"Streidl","year":"2021","journal-title":"Gut Microbes"},{"key":"B33","doi-asserted-by":"publisher","first-page":"fuad014","DOI":"10.1093\/femsre\/fuad014","article-title":"Ruminococcus gnavus: friend or foe for human health","volume":"47","author":"Crost","year":"2023","journal-title":"FEMS Microbiol Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1904099116","article-title":"Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn's disease, produces an inflammatory polysaccharide","volume":"116","author":"Henke","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e2007595118","DOI":"10.1073\/pnas.2007595118","article-title":"Capsular polysaccharide correlates with immune response to the human gut microbe Ruminococcus gnavus","volume":"118","author":"Henke","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B36","doi-asserted-by":"publisher","first-page":"fix127","DOI":"10.1093\/femsec\/fix127","article-title":"Prebiotic potential of pectin and pectic oligosaccharides to promote anti-inflammatory commensal bacteria in the human colon","volume":"93","author":"Chung","year":"2017","journal-title":"FEMS Microbiol Ecol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207366","article-title":"A review of gut microbiota-derived metabolites in tumor progression and cancer therapy","volume":"10","author":"Yang","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02453-x","article-title":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial","volume":"29","author":"Routy","year":"2023","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1864941\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:37:27Z","timestamp":1787031447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1864941\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2026.1864941"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1864941","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1864941"}}